Neurocrine(US:NBIX) Financial Modeling Prep·2025-11-28 19:00Core Insights - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical company focused on neurological and endocrine-related disorders, known for its innovative therapies and strong market presence [1] - Canaccord Genuity has reiterated a "Buy" rating for NBIX, indicating confidence in the company's future performance, while suggesting a "hold" action for investors [2] - Capital Fund Management S.A. increased its holdings in NBIX by 15.9%, now owning 203,628 shares valued at approximately $25.6 million, reflecting belief in the company's growth potential [3] - Other institutional investors, such as Geneos Wealth Management Inc. and WPG Advisers LLC, have also adjusted their positions, indicating growing interest in NBIX [4] - The current stock price of NBIX is $151.58, reflecting a 5.61% increase, with a market capitalization of approximately $15.07 billion [5][6]